AB SCIEX has been launched as a new company dedicated to life science analytical technologies. The new company is formed from the combination of the two halves of the AB SCIEX mass spectrometry joint venture.
AB SCIEX has been launched as a new company dedicated to life science analytical technologies. The new company is formed from the combination of the two halves of the AB SCIEX mass spectrometry joint venture.
“This integrated company will be able to shape the future of mass spectrometry in ways far greater than what we have already achieved,” said Laura Lauman, the company’s president, in a statement. According to Lauman, bringing the former joint venture together will enable the company to “keep pace with the dynamic needs of the life science industry.”
The company provides instrumentation, software and services used in a number of life science applications, including drug discovery and development, disease studies and food and environmental safety. These include integrated LC–MS–MS platforms for small molecule analysis, contaminant identification and biomarker validation, as well as MALDI TOF/TOF systems for protein biomarker discovery.
For more information about the company go to www.absciex.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.